Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guerin (BCG)-unresponsive High-Risk (HR) Non-Muscle-Invasive Bladder Cancer (NMIBC)

被引：0

作者：

Gupta, S. ^{[1
]}

Kulkarni, G. ^{[2
,3
]}

Necchi, A. ^{[4
]}

Shore, N. D. ^{[5
]}

Dave, H. ^{[6
]}

Kapadia, E. ^{[6
]}

Zhao, Q. ^{[6
]}

Kamat, A. ^{[7
]}

机构：

[1] Cleveland Clin, Dept Genitourinary Oncol, Taussig Canc Ctr, Cleveland, OH USA

[2] Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada

[4] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Dept Med Oncol, Milan, Italy

[5] Carolina Urol Res Ctr, Dept Oncol, Myrtle Beach, SC USA

[6] Merck & Co Inc, Dept Clin Res, Rahway, NJ USA

[7] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX USA

来源：

EUROPEAN UROLOGY | 2024年 / 85卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

P312

引用

页码：S433 / S433

页数：1

共 50 条

[1] Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C
Necchi, A.
Shore, N. D.
Gupta, S.
Kulkarni, G.
Dave, H.
Kapadia, E.
Zhao, Q.
Kamat, A.
[J]. EUROPEAN UROLOGY, 2023, 83 : S748 - S748
[2] Phase 2 KEYNOTE-057 cohort C: Pembrolizumab (pembro) with vibostolimab or favezelimab for patients (pts) with high-risk (HR) bacillus Calmette-Gu ′erin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC).
Shore, Neal D.
Gupta, Shilpa
Kulkarni, Girish S.
Necchi, Andrea
Dave, Hema Kishore
Kapadia, Ekta
Zhao, Qing
Kamat, Ashish M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[3] Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C.
Kulkarni, Girish S.
Gupta, Shilpa
Necchi, Andrea
Shore, Neal D.
Dave, Hema Kishore
Kapadia, Ekta
Zhao, Qing
Kamat, Ashish M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS719 - TPS719
[4] Pembrolizumab in patients with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
de Wit, R.
Kamat, A. M.
Bellmunt, J.
Choueiri, T. K.
Nam, K.
De Santis, M.
Dreicer, R.
Hahn, N. M.
Perini, R.
Siefker-Radtke, A. O.
Sonpavde, G.
Witjes, J. A.
Keefe, S.
Bajorin, D.
[J]. ANNALS OF ONCOLOGY, 2016, 27
[5] Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Phase II KEYNOTE-057 trial
de Wit, R.
Kulkarni, G. S.
Uchio, E.
Singer, E. A.
Krieger, L.
Grivas, P.
Bajorin, D.
Seo, H. K.
Mourey, L.
Kamat, A.
Nishiyama, H.
Kapadia, E.
Nam, K.
Frenkl, T.
Balar, A.
[J]. ANNALS OF ONCOLOGY, 2018, 29 : 304 - 304
[6] KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)
Kamat, Ashish M.
Bellmunt, Joaquim
Choueiri, Toni K.
Nam, Kijoeng
De Santis, Maria
Dreicer, Robert
Hahn, Noah M.
Perini, Rodolfo F.
Siefker-Radtke, Arlene O.
Sonpavde, Guru
De Wit, Ronald
Witjes, Alfred
Keefe, Stephen Michael
Bajorin, Dean F.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG): EFFICACY AND EVALUATION OF SUBSEQUENT CYSTECTOMY FROM COHORT B OF THE PHASE 2 KEYNOTE-057 STUDY
Singer, Eric
Necchi, Andrea
Roumiguie, Mathieu
Esen, Ahmet Adil
Lebret, Thierry
de Wit, Ronald
Bajorin, Dean F.
Krieger, Laurence E. M.
Kandori, Shuya
Uchio, Edward M.
Seo, Ho Kyung
Boormans, Joost
Kamat, Ashish M.
Grivas, Petros
Nishiyama, Hiroyuki
Baranwal, Pranshu
Kapadia, Ekta
Van den Sigtenhorst-Fijlstra, Margot
Kulkarni, Girish S.
Shore, Neal D.
[J]. JOURNAL OF UROLOGY, 2023, 209 : E1195 - E1195
[8] Updated Interim Analysis from Keynote-057: Pembrolizumab Monotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Krieger, Laurence
de Wit, Ronald
Kulkarni, Girish S.
Uchio, Edward M.
Boormans, Joost L.
Roumiguie, Mathieu
Singer, Eric A.
Bajorin, Dean F.
Kamat, Ashish M.
Grivas, Petros
Seo, Ho Kyung
Nishiyama, Hiroyuki
Konety, Badrinath R.
Nam, Kijoeng
Kapadia, Ekta
Frenkl, Tara L.
Balar, Arjun Vasant
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 52 - 53
[9] Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG).
Balar, Arjun Vasant
Kulkarni, Girish S.
Uchio, Edward M.
Boormans, Joost
Mourey, Loic
Krieger, Laurence Eliot Miles
Singer, Eric A.
Bajorin, Dean F.
Kamat, Ashish M.
Grivas, Petros
Seo, Ho Kyung
Nishiyama, Hiroyuki
Konety, Badrinath R.
Nam, Kijoeng
Kapadia, Ekta
Frenkl, Tara L.
De Wit, Ronald
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[10] OUTCOMES IN PATIENTS (PTS) WITH BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE HIGH-RISK (HR) NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) WHO UNDERWENT RADICAL CYSTECTOMY (RC) FOLLOWING PEMBROLIZUMAB (PEMBRO) TREATMENT IN KEYNOTE-057 COHORT A
Kulkarni, Girish S.
Kamat, Ashish M.
Uchio, Edward M.
Roumiguie, Mathieu
Krieger, Laurence E. M.
Singer, Eric A.
Bajorin, Dean F.
Grivas, Petros
Seo, Ho Kyung
Nishiyama, Hiroyuki
Konety, Badrinath R.
De Wit, Ronald
Kapadia, Ekta
Xing, Aiwen
Fijlstra, Margot Van den Sigtenhorst
Boormans, Joost L.
[J]. JOURNAL OF UROLOGY, 2023, 209 : E872 - E873

← 1 2 3 4 5 →